In this issue:
Mirikizumab for moderate-to-severe plaque psoriasis
Psoriasis and psychiatric hospitalisation in the USA
Evaluation of a screening questionnaire for psychological distress
Secukinumab in a real-life clinical setting
Epidermal function and relapse of psoriasis
Adalimumab for nail psoriasis
Efficacy of ixekizumab following secukinumab failure
IL-17A-inhibitor response not explained by genetic variation
Pruritic characteristics of psoriasis
High burden of obesity in German psoriasis patients
Remission/long-term outcomes in psoriasis treated with biologics or tofacitinib
Please login below to download this issue (PDF)